Ignite Creation Date:
2025-12-25 @ 12:01 AM
Ignite Modification Date:
2025-12-25 @ 9:59 PM
Study NCT ID:
NCT06708858
Status:
RECRUITING
Last Update Posted:
2024-11-27
First Post:
2024-11-11
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Phase Ⅱ Clinical Study of Surufatinib Combined With Gemcitabine and Cisplatin Plus Durvalumab/Pembrolizumab Regimen in the Treatment of Advanced Biliary Tract Cancer
Sponsor:
Dai, Guanghai
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2024-08-15
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-07
Completion Date Type:
ESTIMATED
First Submit Date:
2024-11-11
First Submit QC Date:
None
Study First Post Date:
2024-11-27
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-11-26
Last Update Post Date:
2024-11-27
Last Update Post Date Type:
ACTUAL